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we propose that LP activation is a major contributor renal diseases. Here we report new data that may help
explain this open field.to renal damage in APSGN, because MASP-1 directly
We examined the expression of EPO-R by immuno-activates C3 [4] and MASP-2 activates C4 [3]. Both
histochemistry using anti-EPO-R antibody (Upstate Bio-events are followed by activation of the alternative path-
technology, Inc., Lake Placid, New York, USA). Renalway, resulting in the strong deposition of C3 break down
biopsy specimens from 27 patients were examined: pa-products. In addition, lectin recognition (innate immu-
tients with minimal change disease (MCD) (N 5 4), IgAnity) is important at the very early stage in pathogen
nephropathy (IgAN) (N 5 15), membranoproliferativeinvasion, until the antigen-antibody system (acquired im-
glomerulonephritis (MPGN) (N 5 3), crescentic glomer-munity) awakens. Thus, the evidence of LP activation
ulonephritis (CrsGN) (N 5 4). The intensity of glomeru-in APSGN may explain the pathogenesis of this disease.
lar staining was scored using a scale of 0 to 4 as described
Isao Ohsawa, Hiroyuki Ohi, Morito Endo, previously [2]. In MCD, a weak immunoreactivity forTakayuki Fujita, Misao Matsushita and Teizo Fujita
EPO-R was observed in glomerular endothelial cells andDepartment of Internal Medicine II,
Nihon University School of Medicine, Tokyo, Japan on the luminal side of distal tubules (Fig. 1A). In contrast,
Department of Biochemistry, Fukushima Medical University immunoreactivity was high in glomerular endothelial
School of Medicine, Fukushima, Japan cells, mesangial cells and tubulointerstitial lesions in
IgAN, MPGN, and CrsGN. A significantly high glomeru-Correspondence to Isao Ohsawa, M.D., Department of Internal Med-
icine II, Nihon University School of Medicine, Oyaguchi-kamimachi lar staining score was noted in IgAN (2.3 6 0.4; Fig. 1B),
30-1, Itabashi-ku, Tokyo 173-8610, Japan CrsGN (2.9 6 0.4), MPGN (3.0 6 0.4) compared to those
of MCD (1.1 6 0.4).
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High expression of
erythropoietin receptor in
human chronic progressive
glomerulonephritis
To the Editor: In a recent issue of Kidney Interna-
tional, the expression of the erythropoietin-receptor
(EPO-R) was discussed in human and rat kidneys and
in several kidney cell lines [1]. However, additional stud-
ies are necessary to understand the function of this recep-
tor in vivo. Since erythropoietin (EPO) is widely used
Fig. 1. Immunohistological staining of EPO-R in MCD and IgAN. (A)in patients with renal anemia, we believe it is necessary to
Small arrowhead shows weak immunoreactivity in glomerular endothe-
investigate the role of this receptor in human progressive lial cells in MCD. Arrowhead shows immunoreactivity at the luminal
side of distal nodules. Some proximal tubules also showed diffuse weak
positive staining. (B) Increased immunoreactivity was observed in glo-
merular endothelial cells (arrowheads). The tubulointerstitial area dem-
onstrates strong immunoreactivity for EPO-R in IgAN. 1999 by the International Society of Nephrology
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Medicine and Division of Nephrology, Seirei Hamamatsufound a proliferative effect of EPO-R in cultured tubular
General Hospital, Hamamatsu, Japancells. Furthermore, using EPO-dependent human leuke-
Correspondence to Naoki Ikegaya, M.D., First Department ofmia cell line UT-7, Komatsu et al [3] found that the
Medicine, Hamamatsu University School of Medicine,expression of the EPO-R gene is dependent on cell cycle;
3600 Handa-cho, Hamamatsu, 431-3192, Japan
these authors reported a low level of EPO-R mRNA
expression at the G0/G1 phase but overexpression at REFERENCES
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